studies

head and neck cancer squamous cell cancer (HNSCC), durvalumab based treatment vs. durvalumab alone, meta-analysis of study results

No data for this selection

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 6,275,106,104,105,276,103,277,102,109,278,101,192,114 - treatments: 854,374,953,672,1080,1560,1073,862